Press Releases

Data Anticipated Q4 2020 Jul 08, 2020, 07:30 ET CRANBURY, N.J., July 8, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced reinitiation of enrollment of its Phase 2 study with […]

– Limited to Proposal 4, Amendment to Certificate of Incorporation to Increase Authorized Common Stock – Proposals 1, 2, 3 and 5 were approved at the Annual Meeting – Scheduled to Reconvene July 23, 2020, 9:00 am Eastern Daylight Time Jun 29, 2020, 07:30 ET CRANBURY, N.J., June 29, 2020 /PRNewswire/ — Palatin Technologies, Inc. (“Palatin”)

– Engages with Scientific, Governmental and Regulatory Agencies – Targeting Q4 2020 Initiation of an Adaptive Phase 2 Trial Jun 23, 2020, 07:30 ET CRANBURY, N.J., June 23, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide

– Dry Eye Disease Phase 2 Study Remains on Track – Data Anticipated in 4Q20 – $89 Million in Cash at March 31, 2020 – Teleconference and Webcast to be held on May 12, 2020 May 12, 2020, 07:30 ET CRANBURY, N.J., May 12, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical

May 07, 2020, 07:30 ET CRANBURY, N.J., May 7, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter fiscal year 2020 operating results on Tuesday, May 12, 2020 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive

– Dry Eye Disease Phase 2 Study Remains on Track – Data Anticipated in 4Q20 – $89 Million in Cash at March 31, 2020 CRANBURY, N.J., April 30, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic

– Study Results Expected Q4 2020 Feb 19, 2020, 07:30 ET CRANBURY, N.J., Feb. 19, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced that it has enrolled the first patient

— Dry Eye Disease Phase 2 Study to Commence Q1 2020 — Data Q4 2020 — Approximately $92 Million in Cash and Cash Equivalents at December 31, 2019 — AMAG Announced Plans to Divest Vyleesi® for Premenopausal Women with Hypoactive Sexual Desire Disorder (HSDD) — Teleconference and Webcast to be held on February 11, 2020

Feb 06, 2020, 07:30 ET CRANBURY, N.J., Feb. 6, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2020 operating results on Tuesday, February 11, 2020 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its

– Vyleesi® for Premenopausal Women with Hypoactive Sexual Desire Disorder (HSDD) – AMAG to Divest Asset – Dry Eye Disease Phase 2 Study to Commence Q1 2020 – Data Q4 2020 – Approximately $92 Million in Cash and Cash Equivalents at December 31, 2019 Jan 21, 2020, 07:30 ET CRANBURY, N.J., Jan. 21, 2020 /PRNewswire/